Ankastim

**Ankastim** is an investigational allogeneic donor natural killer cell therapy being developed by Alphageneron Pharmaceuticals for oncology. Based on the provided context, it is a genetically edited NK cell product intended to exert **immunologic cytotoxicity** through replacement or augmentation of antitumor NK cell activity, with preclinical studies reporting cancer cell killing across multiple tumor models. The program appears to be in the **preclinical** stage overall, with a planned Phase 1 combination study in metastatic colorectal cancer in the United States; additional active development has been noted in glioblastoma and non-small cell lung cancer.

Other names

allogeneic donor genetically edited NK cell therapy